Organon will also furnish Dermavant with a $75 million milestone payment contingent upon Vtama’s approval in atopic ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...

Organon is set to acquire Roivant Sciences' Dermavant Sciences, known for developing immuno-dermatology treatments, including ...

Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on Wednesday said it will make an ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), retaining the price target of ...

However, Organon was down 1.4%. Dermavant's Vtama cream, approved by the U.S. Food and Drug Administration in May 2022, treats psoriasis, a common long-term inflammatory skin disease. The FDA is also ...